Literature DB >> 16374636

T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells.

Gretchen E Lyons1, Jeffrey J Roszkowski, Stephen Man, Cassian Yee, W Martin Kast, Michael I Nishimura.   

Abstract

Genetic transfer of T-cell receptor (TCR) chains provides a means of transferring tumor antigen specificity onto an alternate T-cell population. To determine which tumor reactive TCRs are best suitable for such adoptive transfer, careful evaluation of the resulting TCR modified populations need to be performed. We have previously cloned, and expressed TCRs from melanoma, EBV, HCV, and HPV reactive T-cell clones and found that several routine indicators of T-cell function do not always predict the relative strength of a TCR. Using a combination of tetramer binding assays and antigen recognition assays, we identified TCRs that fall into three classes. One class of TCR did not bind tetramers yet resulted in cells with high avidity for antigen. A second TCR class bound tetramer but did not secrete cytokines in response to antigen. Finally, the third class of TCRs bound tetramer and reacted to antigen as would be expected. We conclude that tetramer binding is not always a good indicator of the function of a cloned TCR or the avidity of a TCR gene modified T cell. Furthermore, our data indicate that the use of tetramer binding alone to identify antigen reactive TCRs may result in the exclusion of TCRs that may be highly reactive or cross reactive to the relevant tumor antigen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16374636     DOI: 10.1007/s00262-005-0103-9

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  13 in total

1.  An Engineered T Cell Receptor Variant Realizes the Limits of Functional Binding Modes.

Authors:  Nishant K Singh; Jesus A Alonso; Daniel T Harris; Scott D Anderson; Jiaqi Ma; Lance M Hellman; Aaron M Rosenberg; Elizabeth M Kolawole; Brian D Evavold; David M Kranz; Brian M Baker
Journal:  Biochemistry       Date:  2020-10-19       Impact factor: 3.162

2.  Benzofuran sulfonates and small self-lipid antigens activate type II NKT cells via CD1d.

Authors:  Catarina F Almeida; Dylan G M Smith; Tan-Yun Cheng; Chris M Harpur; Elena Batleska; Catriona V Nguyen-Robertson; Tram Nguyen; Tamara Thelemann; Scott J J Reddiex; Shihan Li; Sidonia B G Eckle; Ildiko Van Rhijn; Jamie Rossjohn; Adam P Uldrich; D Branch Moody; Spencer J Williams; Daniel G Pellicci; Dale I Godfrey
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-24       Impact factor: 11.205

Review 3.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

Review 4.  Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

Authors:  Shreya Kanodia; Diane M Da Silva; W Martin Kast
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

Review 5.  Minor histocompatibility antigens and the maternal immune response to the fetus during pregnancy.

Authors:  Caitlin Linscheid; Margaret G Petroff
Journal:  Am J Reprod Immunol       Date:  2013-02-08       Impact factor: 3.886

6.  Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.

Authors:  Tamson V Moore; Gretchen E Lyons; Natasha Brasic; Jeffrey J Roszkowski; Simon Voelkl; Andreas Mackensen; W Martin Kast; I Caroline Le Poole; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2008-10-03       Impact factor: 6.968

Review 7.  Tricks with tetramers: how to get the most from multimeric peptide-MHC.

Authors:  Linda Wooldridge; Anna Lissina; David K Cole; Hugo A van den Berg; David A Price; Andrew K Sewell
Journal:  Immunology       Date:  2009-02       Impact factor: 7.397

8.  Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers.

Authors:  J Joseph Melenhorst; Phillip Scheinberg; Pratip K Chattopadhyay; Anna Lissina; Emma Gostick; David K Cole; Linda Wooldridge; Hugo A van den Berg; Ethan Bornstein; Nancy F Hensel; Daniel C Douek; Mario Roederer; Andrew K Sewell; A John Barrett; David A Price
Journal:  J Immunol Methods       Date:  2008-07-31       Impact factor: 2.303

Review 9.  Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8+ T cells with peptide-major histocompatibility complex class I tetramers.

Authors:  Pratip K Chattopadhyay; J Joseph Melenhorst; Kristin Ladell; Emma Gostick; Phillip Scheinberg; A John Barrett; Linda Wooldridge; Mario Roederer; Andrew K Sewell; David A Price
Journal:  Cytometry A       Date:  2008-11       Impact factor: 4.355

10.  Phospho-specific flow cytometry for pharmacodynamic monitoring of immunosuppressive therapy in transplantation.

Authors:  Carla Baan; Anne Bouvy; Ramin Vafadari; Willem Weimar
Journal:  Transplant Res       Date:  2012-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.